infliximab biosimilars rheum
Selected indexed studies
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Ann Rheum Dis, 2023) [PMID:36357155]
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. (Ann Rheum Dis, 2020) [PMID:31969328]
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. (Ann Rheum Dis, 2023) [PMID:36368906]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023) pubmed
- Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. (2020) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. (2026) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. (2020) pubmed
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. (2023) pubmed
- Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. (2020) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. (2017) pubmed
- Clinical trials of biosimilars should become more similar. (2017) pubmed
- Are There Benefits and Risks to Biosimilars from a Patient Perspective? (2019) pubmed
- Biosimilar safety factors in clinical practice. (2015) pubmed